Psychedelic use and psychiatric risks.
Otto Simonsson, Simon B. Goldberg, Richard Chambers, Walter Osika, Charlotta Simonsson, Peter S. Hendricks
Psychopharmacology July 1, 2025 DOI: 10.1007/s00213-023-06478-5 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Cross-sectional survey Longitudinal Peer reviewed |
|---|---|
| Sample size | 2,822 |
| Population | US adult population representative by sex, age, and ethnicity |
| Keywords | Hppd Psychedelics Psychotic Risks Visual |
| Citations | 33 |
| Key findings | Lifetime psychedelic use was associated with more unusual visual experiences but not with past 2-week psychotic symptoms; an interaction with family history of psychotic or bipolar disorders was observed. |
Abstract
Research on psychedelics has recently shown promising results in the treatment of various psychiatric disorders, but relatively little remains known about the psychiatric risks associated with naturalistic use of psychedelics. The objective of the current study was to investigate associations between naturalistic psychedelic use and psychiatric risks. Using a sample representative of the US adult population with regard to sex, age, and ethnicity (N=2822), this study investigated associations between lifetime naturalistic psychedelic use, lifetime unusual visual experiences, and past 2-week psychotic symptoms. Among respondents who reported lifetime psychedelic use (n=613), 1.3% reported having been told by a doctor or other medical professional that they had hallucinogen persisting perception disorder. In covariate-adjusted linear regression models, lifetime psychedelic use was associated with more unusual visual experiences at any point across the lifetime, but no association was observed between lifetime psychedelic use and past 2-week psychotic symptoms. There was an interaction between lifetime psychedelic use and family (but not personal) history of psychotic or bipolar disorders on past 2-week psychotic symptoms such that psychotic symptoms were highest among respondents who reported lifetime psychedelic use and a family history of psychotic or bipolar disorders and lowest among those who reported lifetime psychedelic use and no family history of psychotic or bipolar disorders. Although the results in this study should be interpreted with caution, the findings suggest that lifetime naturalistic use of psychedelics might be associated with more unusual visual experiences across the lifetime, as well as more psychotic symptoms in the past 2 weeks for individuals with a family history of psychotic or bipolar disorders and the reverse for those without such a family history. Future research should distinguish between different psychotic and bipolar disorders and should also utilize other research designs (e.g., longitudinal) and variables (e.g., polygenic risk scores) to better understand potential cause-and-effect relationships.
Citations in the library
Cited by 27
- Longitudinal associations between psychedelic use and psychotic symptoms in the United States and the United Kingdom Journal of Affective Disorders January 26, 2024
- Navigating groundlessness: An interview study on dealing with ontological shock and existential distress following psychedelic experiences. PLoS One 2025
- Psilocybin therapy for mood dysfunction in Parkinson's disease: an open-label pilot trial. Neuropsychopharmacology April 9, 2025
- Longitudinal associations of naturalistic psychedelic use with psychotic and manic symptoms. Psychological Medicine March 31, 2025
- Neurocognitive effects of psilocybin: A systematic and comprehensive review of neuroimaging studies in humans. Neuroscience & Biobehavioral Reviews August 1, 2025
and 22 more in the library
Cites 17
- Trial of Psilocybin versus Escitalopram for Depression New England Journal of Medicine April 14, 2021
- Human hallucinogen research: guidelines for safety. Journal of Psychopharmacology July 1, 2008
- Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine November 3, 2022
- Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern‐era clinical studies Acta Psychiatrica Scandinavica October 30, 2020
- Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial. EClinicalMedicine February 1, 2023
and 12 more in the library